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Abstract
Background: There is increasing evidence that unacylated ghrelin (UAG) improves insulin sensitivity and glucose
homeostasis; however, the mechanism for this activity is not fully understood since a UAG receptor has not been
discovered.
Methodology/Principal Findings: To assess potential mechanisms of UAG action in vivo, we examined rapid effects of UAG
on genome-wide expression patterns in fat, muscle and liver of growth hormone secretagogue receptor (GHSR)-ablated
mice using microarrays. Expression data were analyzed using Ingenuity Pathways Analysis and Gene Set Enrichment
Analysis. Regulation of subsets of these genes was verified by quantitative PCR in an independent experiment. UAG acutely
regulated clusters of genes involved in glucose and lipid metabolism in all three tissues, consistent with enhancement of
insulin sensitivity.
Conclusions/Significance: Fat, muscle and liver are central to the control of lipid and glucose homeostasis. UAG rapidly
modulates the expression of metabolically important genes in these tissues in GHSR-deleted mice indicating a direct, GHSR-
independent, action of UAG to improve insulin sensitivity and metabolic profile.
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Introduction
Ghrelin was initially identified as a potent GH secretagogue [1]
and is O-octanoylated at Ser3 (acylated ghrelin, AG) by ghrelin O-
acyl transferase (GOAT) [2,3], a posttranslational modification
required for its activation of the growth hormone secretagogue
receptor (GHSR). However, only 5–20% of circulating ghrelin is
acylated, the predominant form being unacylated (UAG) [4]. At
first UAG was considered an inactive form of ghrelin, although
accumulating evidence indicates that UAG can modulate
metabolic activities of the ghrelin system either independently or
in opposition to those of AG. Examples of these UAG actions
include improvement of pancreatic b-cell function and survival
[5,6], and a beneficial role in cardiovascular function [4,7]. These
activities of UAG would likely have important implications in the
progression of the metabolic syndrome. Although evidence exists
in these and other systems that UAG acts via a GHSR-
independent mechanism, it remains unclear if this is the case for
direct regulation of metabolic pathways.
This study aims to address the hypotheses that: a) UAG
modulates the expression of genes encoding components of lipid
and carbohydrate metabolic pathways, b) UAG acts via a GHSR-
independent mechanism. The development of type 2 diabetes
(T2D) stems from the suppression of insulin sensitivity in three key
organs: the liver, muscle and adipose. The basis for this is
deranged lipid metabolism in parallel with altered carbohydrate
metabolic pathways. In humans, our published data suggest that
UAG can improve insulin sensitivity by modulating lipid
metabolism; the co-administration of AG and UAG reduces
plasma FFA in GH-deficient patients [8] and the continuous
infusion of UAG decreases FFA in healthy and diabetic subjects
[9]. This agrees with the findings that fat-specific overexpression of
UAG in mice lowers fat mass and improves insulin sensitivity [10],
and that UAG has direct effects on adipose tissue in vitro [11,12].
We have also shown that AG and UAG modulate hepatocyte
function in which glucose output was stimulated by AG and
inhibited by UAG [13]. Like our clinical data, this study showed
that UAG counteracts AG stimulated glucose release. The in vivo
effects of AG and UAG on hepatic insulin sensitivity have been
further examined by hyperinsulinemic-euglycemic clamp [14]. It
was shown that co-administration of UAG with AG neutralizes the
insulin desensitizing effects of AG administration, and normalizes
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Jhepatic insulin sensitivity, reinforcing our idea that UAG opposes
AG in regulating hepatic glucose metabolism. That the relation-
ship between AG and UAG may have an impact on metabolism
has been suggested from clinical studies which show an indirect
relationship between circulating AG/UAG ratio and insulin
resistance [15], and a decreased AG/UAG ratio in fasting,
relatively insulin sensitive, subjects [16].
There is, therefore, indirect evidence that UAG (and AG/UAG
ratio) alters lipid and glucose homeostasis in vivo, but no direct
evidence that it can regulate metabolic pathways that control these
processes or of the cellular mechanism(s) involved. To address the
hypothesis that UAG can modulate metabolic pathways relevant
to insulin sensitivity, we used an unbiased approach: transcrip-
tome-wide expression profiling of liver, muscle and white adipose
tissue (WAT). The study examined acute effects of UAG to dissect
its direct effects on the tissues examined, including possible
signaling pathways. To test the hypothesis that UAG acts
independently of the GHSR we examined the effects of UAG
on tissues in Ghsr knockout mice [17]. Finally, the hypothesis that
AG interacts with UAG in regulating metabolic pathways, we
examined the effects of UAG on tissues in wild type mice. We find
that UAG regulates genes involved in lipid and carbohydrate
metabolic pathways in all three tissues in a direction that indicates
an overall improvement in metabolic profile, independently of the
GHSR.
Results
Ingenuity Pathways Analysis (IPA)
The main finding from the microarray experiment was that
UAG caused rapid changes in expression of hundreds of genes in
all three tissues examined in adult Ghsr knockout mice (Fig. 1).
Initially we assessed ‘‘regulated’’ (UAG/wild type ratio $2o r
#0.5) genes in normalized Affymetrix array datasets using
Ingenuity Pathways Analysis (IPA, www.ingenuity.com).
Overall, in Ghsr deficient mice, UAG modulated by greater than
2-fold the signal from 374 Probe Set IDs in WAT, 131 in muscle
and 151 in liver (data corrected using the Benjamini-Hochburg
multiple testing method, with effects considered significant at
p,0.05). This reflects our findings, and that of others, that UAG
influences insulin sensitivity by modulating fat metabolism [10,18].
After collapsing the IDs into known gene symbols, 226 genes were
eligible for pathway analysis in WAT; nearly three times the
number that were regulated by 2-fold or more in muscle (80 genes)
and liver (81 genes). Of these, several were directly linked with
lipid and carbohydrate metabolic pathways (Fig. 1). The majority
of genes linked with these two pathways in WAT were down-
regulated, whereas in muscle up and down-regulated genes were
evenly balanced. In contrast, in liver most genes linked with lipid
and carbohydrate metabolism were up-regulated, predominantly
in the lipid metabolism pathway.
The data shown in Fig. 1 are based on initial IPA Functional
Analyses of the datasets and are derived from the Molecular and
Cellular Functions data subset. UAG regulated genes were also
significantly linked with other pathways (Table 1). From this
analysis it is clear that although UAG-regulated genes show
significant associations with lipid and glucose metabolic pathways
in all tissues, in muscle and liver these genesets ranked lower in
terms of p-value than in WAT. UAG regulated genes in WAT
were associated with 24 functions of which lipid and carbohydrate
metabolism ranked 4
th and 2
nd, respectively. On the other hand,
these functions ranked 8
th and 16
th of 25 functions in muscle and
11
th and 23
rd of 27 functions in liver. Many of the top functions
were linked with cell growth and proliferation, indicating effects on
tissue differentiation or growth.
In all tissues at least one of the top molecular and cellular
functions was related to cell signaling, although no obvious
common pathway was regulated. However, expression of genes
encoding several G-protein coupled receptors and their regulatory
proteins were modulated in WAT, and to a lesser extent in muscle
(Table 2).
Having established that, in the absence of the GHSR, UAG
regulates gene expression in WAT, muscle and liver, we asked if
the pattern of gene expression amongst these tissues was similar.
This could suggest commonalities in UAG’s mechanism of action.
Of the total of 353 genes, less than 1% are regulated by UAG in all
three tissues (Fig. 2). Interestingly, one of these 3 genes was Cebpd.
CAAT enhancer binding protein d (C/EBPd) is an important
initiator of adipocyte differentiation, and is involved in myocyte
and hepatocyte differentiation. In an independent experiment
Figure 1. UAG regulates lipid and carbohydrate metabolic pathway genes in fat, muscle and liver of Ghsr KO mice. Datasets including
two-fold, or greater, regulated genes from each tissue were interrogated by Ingenuity Pathways Analysis for association with all included pathways.
Probabilities for random association (false discovery rate) were adjusted using the Benjamini-Hochburg multiple testing correction method. For lipid
and carbohydrate metabolic pathways in the fat and liver datasets adjusted p was ,0.0017, and in the muscle dataset adjusted p was ,0.0012.
doi:10.1371/journal.pone.0011749.g001
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WAT and muscle, and showed a trend to increase in liver. Fkbp5
(FK506 BP5) and Slc15a2 (proton/oligopeptide transporter) are
also regulated by UAG in all three tissues, although their function
in these settings is unclear. The greatest overlap of UAG regulated
genes occurred between WAT and muscle (Fig. 2), particularly
those encoding enzymes involved in fatty acid synthesis (Acaca,
Acly, Gyk and Elovl6), glucose transport (Slc2a5), the ox-phos
pathway (Gpd2), and adipogenesis (Cebpd, Lep). Importantly, these
genes tended to be down-regulated in both WAT and muscle.
Table 1. Top 5 Ingenuity pathway analysis molecular and cellular functions assigned to $2 fold UAG regulated gene sets from fat,
muscle and liver of Ghsr KO mice.
Fat
Function p-value # Molecules
Cell Signaling 4.37E-09–1.44E-02 80
Carbohydrate Metabolism 1.89E-09–1.44E-02 12
Small Molecule Biochemistry 1.89E-09–1.44E-02 27
Lipid Metabolism 9.86E-09–1.44E-02 19
Nucleic Acid Metabolism 9.86E-09–1.44E-02 5
Muscle
Function p-value # Molecules
Cellular Movement 8.13E-09–1.08E-02 24
Cellular Development 1.38E-09–7.37E-02 30
Cell-to-Cell Signaling and Interaction 2.69E-09–1.07E-02 26
Cell Death 2.89E-09–1.08E-02 33
Cellular Growth and Proliferation 8.58E-09–1.07E-02 30
Liver
Function p-value # Molecules
Cell Signaling 2.72E-09–3.06E-02 44
Cellular Growth and Proliferation 1.73E-09–3.06E-02 29
Cell Death 4.23E-09–3.70E-02 31
Cellular Development 1.21E-09–3.41E-02 31
Cell Morphology 3.76E-09–3.37E-02 18
The p-value was derived using Fisher’s Exact test.
doi:10.1371/journal.pone.0011749.t001
Table 2. G-protein coupled receptors and regulatory proteins regulated by acute UAG treatment (none were regulated $2-fold in
liver).
Tissue Probe Set ID Molecules Description UAG/Sal ratio
Fat 1415832_at Agtr2 angiotensin II receptor, type 2 0.4
1425215_at Ffar2 free fatty acid receptor 2 2.1
1419301_at Fzd4 frizzled homolog 4 (Drosophila) 2.2
1418379_s_at Gpr124 G protein-coupled receptor (GPCR) 124 0.5
1427028_at Lgr6 LRR-containing GPCR 6 0.5
1450286_at Npr3 natriuretic peptide receptor C 3.4
1440888_at Oxtr oxytocin receptor 0.3
1440785_at Rxfp1 relaxin/insulin-like family peptide receptor 1 0.4
1425701_a_at Rgs3 regulator of G-protein signaling 3 2.0
1450659_at Rgs7 regulator of G-protein signaling 7 0.5
Muscle 1460123_at Gpr1 GPCR 1 2.1
1457324_at Oprs1 opioid receptor, sigma 1 2.3
1440888_at Oxtr oxytocin receptor 0.4
doi:10.1371/journal.pone.0011749.t002
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Gene Set Enrichment Analysis (GSEA) was used to analyze the
entire microarray data set from each tissue [19].
White adipose tissue. In WAT, UAG upregulated gene sets
for N-glycan degradation, fibrinolysis/complement pathways, the
CD40 pathway, the Akt pathway, and the glutathione metabolic
pathway (Table S1). UAG down-regulated gene sets (Table S2)
relating to fatty acid, cholesterol/steroid and glucose/carbohydrate
metabolism, and mitochondrial respiration (OXPHOS and Krebs/
TCA cycle pathways), as well as gene sets linked with T2D and
Maturity Onset Diabetes of the Young (MODY), and insulin
signaling.
GSEA was also used to interrogate gene sets that contain
specific cis-regulatory elements (Tables S3 & S4). Transcripts of
genes containing E2F, ATF2 and REST cis-elements were
upregulated by UAG in Ghrs KO WAT. Transcripts of genes
containing, for example, SRF, AP2, CEBP, and FOX cis-elements
were downregulated by UAG.
Muscle. In muscle, UAG upregulated gene sets that were
predominantly associated with myocyte (RARALPHA, MYOD_
NIH3T3) and adipocyte (IDX_TSA, NADLER_OBESITY_UP)
differentiation, as well as WNT, IGF-I and insulin signaling (Table
S5). Down-regulated gene sets in muscle include the pentose
phosphate pathway, as well as pathways involved with lipid and
carbohydrate metabolism (Table S6).
Assessment of transcript gene sets containing specific cis-
regulatory elements that were upregulated by UAG in muscle
are detailed in Table S7. These include genes containing E2F, C/
EBP(b/d), CREB, SREBP, GATA, MYOGENIN and MYOD cis-
elements. Transcripts of genes containing HNF1 cis-elements were
downregulated by UAG.
Liver. UAGupregulated gene sets inliver, asinfatandmuscle,
included those related to hepatocyte growth and adipogenesis (eg.
LEE_MYC_E2F1_UP and IDX_TSA_UP_CLUSTER1; Table
S8). Additionally, three gene sets related to mitochondrial oxidative
respiration (HAS00190_OXIDATIVE_PHOSPHORYLATION,
CITRATE_CYCLE_TCA_CYCLE and ELECTRON_TRANS-
PORT_CHAIN) were upregulated. Assessment of transcript gene
sets containing specific cis-regulatory elements that were upregulated
by UAG in liver (Table S9) include ATF, CREBP1 and RSRF4.
Quantitative PCR gene expression confirmation
We next validated the microarray data analyses in an
independent experiment. Six Ghsr knockout mice were injected
with either saline or UAG and 6 hours later tissues were removed
for analysis of gene expression by quantitative PCR. We assessed
genes identified in the initial expression profiling experiment to be
either regulated more than 2-fold by UAG treatment, or those
linked with UAG-regulated pathways identified by GSEA,
particularly lipid and carbohydrate metabolism, and adipogenesis.
Between the two independent (microarray and QPCR) experi-
ments, approximately 70% (15) of the genes assessed show strong
correlation (r
2=0.8, p,0.0001) in direction and magnitude of
regulation by UAG (Figure S1).
White adipose tissue. In gonadal WAT many genes linked
with lipogenesis were significantly down-regulated (Fig. 3). These
include Acaca (acetyl CoA carboxylase a), Acly (ATP citrate lyase),
Acad9 (acetyl CoA dehydrogenase 9), Fasn (fatty acid synthase), Elovl6
(ELOVL family member 6, elongation of long chain fatty acids) and
Gyk (glycerol kinase) (Fig. 3A). Hormone sensitive lipase and lipo-
protein lipase mRNAs (Lipe and Lipd) were significantly increased
(Fig. 3B). Genes that control sterol/cholesterol synthesis are also
regulated. For example, Hmgcs1 (cytosolic hydroxymethylglutaryl
CoA synthase) and Insig1 (insulin induced gene 1) mRNAs are
suppressedand Srebp1c (sterolresponse-elementbindingprotein1c)is
induced (Fig. 3C). There is recent evidence that SREBP1c, in
contrast to its function in liver, regulates cholesterol synthesis not
lipogenesisinfat[20,21].Infatthereappearstobeuncouplingofthis
transcription factor from regulation of genes such as Acaca and Fas,
which could explain our finding that these genes are not coordinated
Figure 2. Overlap in the expression of UAG regulated genes
amongst tissues of Ghsr KO mice. The largest intersecting set
occurs between fat and muscle with 22 genes (Venn diagram). These
genes tend to be regulated in the same direction in both tissues (18 of
21, heat map on right) and include genes that encode key regulatory
enzymes in lipid and carbohydrate metabolism, such as Acaca and Acly.
Intersects between fat and liver, and muscle and liver consist of much
smaller gene sets, but include Camk2b, Ckm, Phgdh and Zbtb16, which
have all been linked with regulation of energy homeostasis and
metabolic syndrome.
doi:10.1371/journal.pone.0011749.g002
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expression is suppressed by approximately 30%, a possible
mechanism for the down-regulation of lipogenic genes, although
this transcription factor preferentially regulates cholesterologenesis
[22]. Further work needs to be performed to determine the
transcriptional mechanisms involved. Insig1 is also a target gene for
PPARc activation, and its down-regulation may be linked with the
down-regulation of both Pparg and Ppargc1a (Fig. 3D).
Down-regulation of the key regulator of adipogenesis, Pparg,
indicated modulation of differentiated state in adipose tissue, as
revealed by GSEA analysis. Additionally, GSEA showed that UAG
altered the expression of genes containing cis-elements that bind
adipogenic transcription factors (eg. E2F, p27, p53, SRF [23]). This
was borne out by the finding that several genes that either regulate,
or are markers for, adipogenesis were altered acutely by UAG
treatment. For example, mRNAs encoding C/EBPa and C/EBPd
were rapidly up- and down-regulated, respectively, by UAG
treatment (Fig. 3E). Lcn2 (lipocalin 2) and Ucp2 (uncoupling protein
2) were markedly suppressed by UAG, indicating improved insulin
signaling. Serpine1 (encoding PAI-1) was increased (Fig. 3F). Based
on GSEA, we also measured expression of genes involved in Notch
signaling (Notch1/4 and Jag1) and matrix remodeling/fibrinolysis
(Mmp9 and Timp4) and found them to be regulated by UAG
(Fig. 3G). These pathways are important for normal adipogenesis
and are altered in obesity [24,25].
Muscle. UAG significantly regulated a number of genes in
muscle that were involved in lipid and carbohydrate metabolism.
Like WAT, the majority of these were downregulated, with a few
exceptions, including Acaca and Gyk, which were significantly
upregulated (Fig. 4A). The key regulator of these processes, Pparg
was suppressed, as well as genes linked with mitochondrial
respiration, such as Ppargc1a and Cpt1b (Fig. 4B). Surprisingly, in
Ghsr KO muscle Acaca was expressed at similar levels to Acacb
(which encodes the predominant form of muscle acetyl CoA
carboxylase, ACC2). However, this gene was not regulated by
UAG treatment. Two genes that are important in the early
regulation of adipogenesis, Cebpd and Foxa1, are also modulated by
UAG (Fig. 4C). Finally, four genes linked with modulation of
insulin sensitivity, Lcn2, Ucp2, Serpine1 and Nox4, are suppressed by
UAG treatment in muscle (Fig. 4D).
Liver. Liver responded differently from WAT and muscle in
that genes encoding components of lipid and carbohydrate
metabolic pathways, if they were regulated at all, were
upregulated (Fig. 5A). This fits with GSEA analyses, where
adipogenic pathway gene sets were upregulated in liver as opposed
to mostly being down-regulated in WAT and muscle. Conversely,
Lcn2 and Nox4, genes linked with insulin sensitivity that were
downregulated in WAT and muscle, were upregulated (Fig. 5B).
Saa1, a marker of high fat diet induced hepatic insulin resistance, is
suppressed by UAG. Lastly, it was found that several upregulated
Figure 3. Confirmation of UAG regulated genes in white adipose tissue. Quantitative PCR measurement of gene expression in an
independent experiment confirms regulation by UAG of genes involved in lipid/cholesterol metabolism, as well as adipocyte differentiation and
insulin-sensitivity in white adipose tissue (WAT). A: Key regulators of fatty acid synthesis, both short and long-chain, were suppressed by UAG
treatment. B: Hormone sensitive lipase (Lipe) and liporotein lipase (Lipd) gene expression is increased. C: Regulators of cholesterol synthesis, Insig1
and Hmgcs1 are suppressed by UAG, whereas Srebp1c is induced. D: Expression of Pparg and its coactivator Ppargc1a, mRNAs that encode key
regulators of lipid synthesis were suppressed by UAG. Pparg is also a key regulator of adipocyte differentiation. E: Key transcriptional regulators of
adipocyte differentiation, Cebpa and Cebpd are up and down-regulated, respectively, by UAG in fat, suggesting suppressive effects on the early stages
of differentiation. F: Regulation of Serpine1, Lcn2 and Ucp2 by UAG indicates improvement of insulin sensitivity in WAT. G: Components of the Notch
signalling (Notch1/4, Jagged1) and the fibrinolytic (Mmp9) pathways (inhibitory and permissive for adipocyte differentiation, respectively) are
regulated by UAG.
doi:10.1371/journal.pone.0011749.g003
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involving GH (Cyp3a16, Igf1), cytokines (Stat3), cAMP (Pde6c) and
PPARc (G0S2) (Fig. 5C).
Discussion
The goal of this study is to identify in an objective way the
effects of UAG on gene expression in metabolically important
tissues in order to extract information about the cellular
mechanism for UAG function in the absence of the GHSR. We
find that UAG generally down-regulates genes that encode
components of lipid and carbohydrate metabolic pathways in
WAT and muscle and up-regulates them in liver, indicating an
overall improvement in metabolic profile. This corroborates
earlier clinical and animal studies showing that UAG can improve
lipid and glucose homeostasis, and demonstrate that UAG has
functional effects on pathways that regulate lipid and glucose
metabolism. Agreement between the independent microarray and
QPCR data strengthen this conclusion. Even more interesting is
the discovery that UAG upregulates pathways involved in insulin
signaling. This suggests direct regulation of insulin sensitivity,
particularly in WAT, as well as cross-talk between UAG and
insulin signaling pathways. Collectively, these effects of UAG are
similar to the finding that partial antagonism, or reduced
expression, of PPARc blocks its obesogenic effects, but maintains
the ability of PPARc to improve insulin sensitivity [26,27].
The second important finding is that peripherally administered
UAG has activity in the absence of the GHSR, as indicated in
pathways analyses by the modulation of diverse signaling pathways
including [Ca
2+]i, cAMP, ‘‘growth factors’’, Notch and Wnt.
Furthermore, the gene expression of a number of G-protein
coupled receptors (GPCR) and their regulatory proteins were
modulated by UAG in WAT and muscle. Such candidate
receptors may be regulated via feedback mechanisms by their
ligands and it is possible that one of them is responding to UAG
treatment. The only GPCR regulated by UAG in both WAT and
muscle was the oxytocin receptor. Oxytocin has been shown to
modulate lipogenesis and glycolysis in fat [28], and more recently
to have metabolic function in skeletal myoblasts and cardiomy-
ocytes [29,30]. However, we have demonstrated in vitro that this
receptor does not signal for UAG (data not shown). Of course, the
UAG receptor could be another class of receptor, such as a
tyrosine kinase receptor. Although no obviously consistent pattern
that could define a UAG signaling pathway was determined, it was
found that there is overlap in the specific genes that are regulated
by UAG in the different tissues, particularly between WAT and
Figure 4. Quantitative PCR measurement of UAG regulated genes in muscle, in an independent experiment. A: Genes encoding
components of fatty acid, triglyceride and cholesterol synthetic pathways. B: Genes encoding key regulators of lipid metabolism and lipid handling.C :
Genes encoding muscle differentiation. D: Genes encoding modulators of insulin sensitivity and signaling.
doi:10.1371/journal.pone.0011749.g004
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in the same direction across tissues pointing to commonality in the
mechanism of UAG action.
White adipose tissue
Lipid metabolism. The main finding of this study is that
UAG suppresses genes that encode key regulatory enzymes
involved in lipogenesis and sterol synthesis in WAT. In relation
to this finding, micro-array data also show .2-fold suppression of
Lipg (endothelial lipase) that mediates uptake of HDL particles and
promotes ApoAI mediated cholesterol efflux [31]. In humans there
is a direct correlation between LIPG levels and BMI and waist
circumference [32]. Insig1 is a target gene for PPARc activation,
and its down-regulation may be linked with the down-regulation of
both Pparg and Ppargc1a. Although UAG treatment of Ghsr
deficient mice primarily affects lipogenesis, we considered that
the lipolytic pathway may also be modulated, since UAG affects
lipolysis in vitro [12]. Because of the high turnover rate of triacyl
glycerol (TAG), an imbalance between the synthesis and hydrolysis
of TAG could lead to the development of obesity [33]. We found
not only that Gyk (glycerol kinase) gene expression was suppressed,
but also that the lipases Lipe and Lipd were moderately, but
significantly, induced by UAG treatment. Furthermore, UAG
treatment caused a trend towards decreased levels of hepatic TAG
after only 6 h (Figure S2).
An unexpected outcome of our analyses was that UAG
increases gene-sets involved in N-glycan degradation in WAT.
Glycosylation is important for GLUT1, GLUT4 and LPL
function, and serum N-linked glycoproteins are increased in obese
diabetic mice and humans [34].
Insulin sensitivity. Upregulation of the Akt/PKB GSEA
geneset is significant since it indicates that the metabolic signalling,
but not the cell proliferation, response to insulin is induced. It has
recently been demonstrated that this pathway is required for insulin
mediated regulation of lipid metabolism in adipocytes [35].
Interestingly, the GSEA insulin signalling geneset (HSA04910_
INSULIN_SIGNALING_PATHWAY) was suppressed by UAG in
WAT. This geneset consists predominantly of genes encoding
participants in the mitogenic IRS-ERK cascade, suggesting that
UAG potentiates the metabolic effects of insulin at the expense of its
proliferative effects.
Lcn2 (lipocalin 2), recently implicated in the development of
obesity and insulin resistance [36,37], was markedly suppressed by
UAG treatment. Suppression of Lcn2 improves insulin sensitivity of
adipocytes in culture and suppresses Pparg gene expression [37].
The corollary of this is that suppression of Lcn2 by UAG improves
insulin sensitivity in fat, and suppresses adipogenesis. Likewise,
Ucp2 was suppressed by UAG in adipose tissue. Suppression of the
Ucp2 gene in vivo causes increased insulin sensitivity in adipose
tissue [38]. The increase in Serpine1 (encoding PAI-1) seems at odds
with the beneficial effects of UAG on lipid and glucose metabolic
pathways. Although PAI-1 levels correlate with adiposity in
obesity, it seems to have no functional role in adipogenesis [39].
Moreover, transgenic over-expression of Serpine1 in mice attenu-
ates diet induced obesity. Recent evidence suggests that PAI-1 is
up-regulated by insulin [40], therefore the increase we observe
may reflect acute improvements in insulin sensitivity in fat.
Adipogenesis. The down-regulation of Pparg also indicates
the modulation of markers of the differentiated state in adipose
tissue, as indicated by the GSEA analyses. This was borne out by
the finding that several genes that either regulate, or are markers
for, adipogenesis were altered by UAG treatment (Fig. 4B). An
outcome of the GSEA was the upregulation of Notch receptors by
UAG, suggesting an additional inhibitory effect on adipogenesis
via this pathway. Another process that is central to the
development of fat is tissue remodeling, identified in both
Ingenuity Pathways analyses and GSEA (fibrinolytic pathway
including matrix metallo-proteases (MMPs)) to be modified by
UAG. One of the key MMPs involved in adipogenesis is MMP9,
which is down-regulated by insulin and, perhaps due to insulin
resistance, raised in obesity [eg.25]. Mmp9 is suppressed by UAG
treatment strongly suggesting an impact on tissue remodeling in
WAT.
Our data clearly fit with those of Zhang et al. [10], who show
that overexpression of UAG in fat cells in vivo suppresses
adipogenesis and fat accumulation. We now show that these
Figure 5. Quantitative PCR measurement of UAG regulated genes in liver, in an independent experiment. A: Genes encoding
components of lipid and cholesterol synthetic pathways. B: Genes encoding modulators of insulin sensitivity and signaling. C: Genes encoding
markers of GH responsiveness and components of intra-cellular signaling pathways.
doi:10.1371/journal.pone.0011749.g005
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UAG in the absence of the GHSR in vivo.
The overall finding in WAT is that UAG suppresses genes
involved in adipogenesis and lipogenesis. This contrasts with AG
which causes the accumulation of lipid in WAT by favoring
expression of lipogenic genes, or altering lipid handling [41,42].
Our findings reinforce the idea that UAG counteracts the effects of
AG on these metabolic pathways particularly in WAT. Impor-
tantly, UAG decreases lipogenesis in fat at the same time as
improving insulin sensitivity.
Muscle
Lipid metabolism. In muscle, both pathway and gene-set
enrichment analyses show effects of UAG treatment on gene
clusters involving adipogenesis. Based on GSEA analyses and
QPCR data UAG also suppresses lipid, sterol and carbohydrate
metabolism-related gene expression. Finally, UAG treatment was
found to suppress gene sets linked with the pentose phosphate (PP)
cycle (Table S6). A major role for the PP pathway is to supply
NADPH for fatty acid synthesis. Thus, inhibition of this pathway
in muscle correlates well with the general suppression of genes that
encode lipogenetic pathways. The mechanism of action of UAG
on this pathway, potentially through regulation of hexose-6-
phosphate dehydrogenase (H6PD), remains to be determined,
although H6PD ablated mice have increased insulin sensitivity in
glycolytic muscle [43], such as the vastus lateralis from which our
data are derived.
Insulin sensitivity. UAG suppressed Cidea gene expression
in muscle, although little is known about its function at this site
[44]. Cidea, like perilipin and adipophilin, localizes at the surfaces
of lipid droplets in adipocytes [45]. Mice lacking Cidea are resistant
to diet-induced obesity and diabetes through modulation of lipid
handling in their tissues [46]. Down-regulation of Cidea suggests
improved insulin sensitivity in muscle, corresponding with up-
regulation of the AKTPATHWAY GSEA geneset (Table S5), and
suppression of Lcn2 and Serpine1 that are linked with worsened
insulin sensitivity [36,37,38].
Adipogenesis. Skeletal muscle contains stem cells, or satellite
cells, that retain broad differentiation capacity including the ability
to generate adipocytes, and myogenic cell lines (eg. C2C12) can be
converted to adipocytes by overexpression of PPARc and C/EBP.
Substitution of muscle with fat strongly correlates with insulin
resistance. Moreover, hyperglycemia in vivo and high-glucose
concentrations in vitro induce de novo lipogenesis and intracellular
lipid accumulation in muscle cells [47]. UAG appears to
counteract these effects by suppressing genes that stimulate
adipogenesis and lipid accumulation. Interestingly, Cebpd and
Foxa1 (encoding HNF3a) were down-regulated. Products of these
genes, as well as Pparg which was also suppressed, are involved in
the early stages of adipogenesis [48], and could indicate
suppression of adipogenesis in muscle. This is a particularly
intriguing finding since it has been shown that the insulin
resistance of morbid obesity can be reversed by intramyocellular
fat depletion [49].
Liver
UAG has very little effect on lipogenic pathways in liver, but
upregulates oxidative phosphorylation (GSEA analyses, Table S8)
and lipid b-oxidation, also indicated by the up-regulation of
Ppargc1a and Acad9 (Fig. 5a). ACAD9 deficiency in humans can
lead to acute liver dysfunction and hypoglycemia, and deletion of
medium chain acyl-CoA dehydrogenase (Acadm), immediately
downstream of Acad9 in the mitochondrial long-chain b-oxidation
pathway, profoundly affects hepatic glucose metabolism [50]. In
contrast, AG treatment up-regulates lipid metabolism genes,
including Acaca and Fasn (and carbohydrate metabolism - G6pc),
and suppresses lipid oxidation as demonstrated by suppression of
Cpt1 [41].
Conclusion
Collectively, our data show that UAG suppresses genes involved
in lipid metabolism, particularly those involved in lipogenesis, in
WAT and muscle. Moreover, the combined effect of UAG is to
enrich indicators of insulin sensitivity in these tissues, in line with
previous clinical and animal studies. Future studies will be directed
to assessing both acute and longer-term effects of UAG on these
specific processes and pathways not only in vivo but also in vitro. The
in vitro work in particular is an important approach to assess our
hypothesis that UAG is having direct effects on peripheral tissues.
Overall, the current study suggests direct action of peripheral
UAG because of the rapidity of its effect on the tissues we have
examined. Moreover, we have found that our Ghsr KO mice show
no modulation of feeding behavior following peripheral (intraper-
itoneal) injection of UAG [51]. It was only upon intra-
cerebroventricular administration that activation of neurons in
the lateral hypothalamic area was induced. Therefore, based on
findings in our Ghsr KO mice we would favour a purely direct
action on peripheral tissues by peripherally administered UAG.
However, in ddY mice, peripherally administered UAG was
shown to stimulate neurons in the hypothalamus, and modulate
food intake [18], although it is not clear in these studies if there is a
causal link. Interestingly, recent studies in rats showed that
peripheral UAG inhibits AG stimulated food intake and
hypothalamic neuron activation [52], but unlike the earlier study
UAG had no independent effect. This relates more closely with
our findings that suggest that UAG does not independently
activate a hypothalamic or central pathway, at least in Ghsr
deficient mice. This is unlike AG, for which regulation of lipid
metabolism has been established to occur via a hypothalamic-relay
involving the sympathetic nervous system [53,54,55,56]. The
model that we have described in this study cannot easily
distinguish between a rapid central and a direct effect of UAG,
and therefore further work is required to dissect a possible central
mechanism of action.
Although the focus of this study was to determine UAG-
dependent effects on metabolic processes, our findings also have
implications for the interaction of UAG with acylated ghrelin.
Findings of our group and others indicate that UAG can act in
opposition to the effects of AG. For example, recent studies
performed in mice have shown that, in contrast to AG, centrally or
intraperitoneally administered UAG induces a negative energy
balance by decreasing food intake and delaying gastric emptying
[18]. Consistent with these results, peripherally injected UAG
blocks the orexigenic effects of AG in rats [52] and transgenic mice
that overexpress UAG in fat had improved insulin sensitivity and
reduced fat mass [10]. In humans, our data also suggest effects on
lipid metabolism; the co-administration of AG and UAG reduces
plasma FFA in GHD patients [8] and the continuous infusion of
UAG [9] decreases FFA in healthy and diabetic subjects,
respectively. The main site of effect amongst the three tissues
examined in Ghsr KO mice was found to be WAT. The effects of
UAG, which may favor decreased adiposity through GHSR-
independent suppression of lipogenetic genes, is in opposition to
the effects of AG to promote fat accumulation through GHSR-
dependent lipid retention [42]. Acylated ghrelin had no effect on
lipogenic genes in white adipose [42], and the apparent difference
in mechanisms of action of UAG and AG on regulation of
UAG, Metabolic Genes
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Materials and Methods
Animals
All animal protocols used were approved by Baylor College of
Medicine Animal Care and Use Committee (Protocol AN-2770).
Twelve week old female Ghsr2/2 mice (.99.9% congenic with
C57BL/6; N12) were kept under conditions of 12:12 h dark:light,
constant temperature, and provided chow and water ad libitum.
Murine UAG (NeoMPS, Strasbourg, France) dissolved in saline
was injected ip. at 20 nmol/kg (200 ml). Controls were injected
with 200 ml of saline. Injections were performed between 3 and
4 hours after lights-on. Mice were provided chow and water ad
libitum until the time of tissue collection. Six hours later animals
were euthanized, and tissues were immediately flash-frozen in
liquid nitrogen. All samples were stored at 280uC until being
processed.
Microarray analysis
RNA was isolated from gonadal white adipose tissue (WAT),
muscle (M. vastus lateralis) and liver of saline and UAG treated
Ghsr2/2 mice (n=2; mean body weight 20.560.1 g) and assessed
for integrity (RNA Integrity Number (RIN) $8.0) on an Agilent
2100 Bioanalyzer (Agilent Technologies, Waldbronn, Ger-
many)[57]. RNA was then processed for hybridization on mouse
Genome 430 2.0 Affymetrix microarrays at the Erasmus Center
for Biomics, using standard Affymetrix protocols. The mean
number of present calls on the arrays was 55.660.6%, and the b-
actin and GAPDH 39/59 ratios were within normal ranges. The
normalized array data have been deposited at the Gene
Expression Omnibus archive, accession number GSE22506.
Real-time quantitative PCR
In a separate experiment, groups of 6 mice (mean body weight
19.960.4 g) were treated in an identical procedure to that
described above. RNA was isolated, and 0.8 mg RNA was reverse
transcribed using M-MLV RT (Promega, The Netherlands) and
an oligo-dT/random hexamer priming mix (Roche, The Nether-
lands). QPCR was performed using a qPCR Core kit for SYBR
Green I (Eurogentec, The Netherlands). Gene-specific primers
were designed to span introns, and data were corrected for b-actin
gene expression (primer sequences available upon request). Gene
expression data derived from quantitative PCR experiments were
analyzed by Student’s t-test, with effects being considered
significant at p,0.05.
Statistical analyses
Array intensities and calls were collected using R, and quantile
normalization was used on one time present calls. An intensity
threshold of 30 was then applied to generate datasets for analysis.
Two-fold regulated genes ($2o r#0.5, calculated as the ratio of
the means) were analyzed using Ingenuity Pathways Analysis
(Ingenuity Systems, www.ingenuity.com). Probabilities for random
association (false discovery rate, FDR) were adjusted using the
Benjamini-Hochburg multiple testing correction method, with
effects being considered significant at p,0.05.
Gene Set Enrichment Analysis software (v. 2.0.4) was used to
analyze the entire data set from each tissue. These data were
initially expressed as log2 ratios of the means of the control and
UAG treated experimental groups. We then used GSEA to
interrogate two a priori defined molecular signature databases at
the Broad Institute (www.broad.mit.edu/gsea/msigdb/index.jsp):
a manually curated pathway database (c2.cp.v2.5.symbols) and a
transcription factor targets database (c3.tft.v2.5.symbols.gmt) [19].
Data are presented if the false discovery rate (FDR) q-value for the
gene set is less than 0.25.
Supporting Information
Figure S1 Approximately 70% of genes assessed by QPCR in fat
from the independent Experiment 2 correlated strongly, in terms
of direction and magnitude of regulation by UAG, with the array
data derived from Experiment 1 (r2, 0.8; p,0.0001).
Found at: doi:10.1371/journal.pone.0011749.s001 (0.07 MB TIF)
Figure S2 Hepatic triglyceride levels show a trend to be
decreased only 6 hours following UAG treatment.
Found at: doi:10.1371/journal.pone.0011749.s002 (0.09 MB TIF)
Table S1 GSEA pathway gene sets up-regulated by UAG in
GHSR KO white adipose tissue. [Size, number of genes in gene
set; ES, enrichment score; NES, normalized enrichment score;
NOM p-val, nominal p-value; FDR q-val, false detection rate q-
value].
Found at: doi:10.1371/journal.pone.0011749.s003 (0.05 MB
DOC)
Table S2 GSEA pathway gene sets down-regulated by UAG in
GHSR KO white adipose tissue. [Size, number of genes in gene
set; ES, enrichment score; NES, normalized enrichment score;
NOM p-val, nominal p-value; FDR q-val, false detection rate q-
value].
Found at: doi:10.1371/journal.pone.0011749.s004 (0.10 MB
DOC)
Table S3 GSEA transcription factor target gene sets up-
regulated by UAG in GHSR KO white adipose tissue. [Size,
number of genes in gene set; ES, enrichment score; NES,
normalized enrichment score; NOM p-val, nominal p-value;
FDR q-val, false detection rate q-value].
Found at: doi:10.1371/journal.pone.0011749.s005 (0.04 MB
DOC)
Table S4 GSEA transcription factor target gene sets down-
regulated by UAG in GHSR KO white adipose tissue. [Size,
number of genes in gene set; ES, enrichment score; NES,
normalized enrichment score; NOM p-val, nominal p-value;
FDR q-val, false detection rate q-value].
Found at: doi:10.1371/journal.pone.0011749.s006 (0.07 MB
DOC)
Table S5 GSEA pathway gene sets up-regulated by UAG in
GHSR KO muscle. [Size, number of genes in gene set; ES,
enrichment score; NES, normalized enrichment score; NOM p-
val, nominal p-value; FDR q-val, false detection rate q-value].
Found at: doi:10.1371/journal.pone.0011749.s007 (0.06 MB
DOC)
Table S6 GSEA pathway gene sets down-regulated by UAG in
GHSR KO muscle. [Size, number of genes in gene set; ES,
enrichment score; NES, normalized enrichment score; NOM p-
val, nominal p-value; FDR q-val, false detection rate q-value].
Found at: doi:10.1371/journal.pone.0011749.s008 (0.07 MB
DOC)
Table S7 GSEA transcription factor target gene sets up-
regulated by UAG in GHSR KO muscle. [Size, number of genes
in gene set; ES, enrichment score; NES, normalized enrichment
score; NOM p-val, nominal p-value; FDR q-val, false detection
rate q-value].
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DOC)
Table S8 GSEA pathway gene sets up-regulated by UAG in
GHSR KO liver. [Size, number of genes in gene set; ES,
enrichment score; NES, normalized enrichment score; NOM p-
val, nominal p-value; FDR q-val, false detection rate q-value].
Found at: doi:10.1371/journal.pone.0011749.s010 (0.13 MB
DOC)
Table S9 GSEA transcription factor target gene sets up-
regulated by UAG in GHSR KO liver. [Size, number of genes
in gene set; ES, enrichment score; NES, normalized enrichment
score; NOM p-val, nominal p-value; FDR q-val, false detection
rate q-value].
Found at: doi:10.1371/journal.pone.0011749.s011 (0.03 MB
DOC)
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